Enzalutamide for the treatment of castration-resistant prostate cancer.
Ha Y, Goodin S, DiPaola R, Kim I. Enzalutamide for the treatment of castration-resistant prostate cancer. Drugs Of Today 2013, 49: 7-13. PMID: 23362491, DOI: 10.1358/dot.2013.49.1.1910724.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerPhase III trialsAndrogen receptorIII trialsProstate cancerTreatment of CRPCMetastatic castration-resistant prostate cancerPhase I/II studyEffectiveness of enzalutamidePrior docetaxel chemotherapyBinding of AROptimal safety profileMajor clinical challengeSignificant antitumor activityPrior chemotherapyDocetaxel chemotherapyII studySafety profileClinical challengePreclinical studiesDrug AdministrationTumor growthChemotherapyU.S. FoodAntitumor activity